LifeMD, Inc. (NASDAQ:LFMD) CEO Sells $334,500.00 in Stock

LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) CEO Justin Schreiber sold 25,000 shares of the company's stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $13.38, for a total value of $334,500.00. Following the transaction, the chief executive officer directly owned 2,500,721 shares in the company, valued at approximately $33,459,646.98. This represents a 0.99% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Justin Schreiber also recently made the following trade(s):

• On Monday, June 2nd, Justin Schreiber sold 25,000 shares of LifeMD stock. The stock was sold at an average price of $12.47, for a total value of $311,750.00.
• On Thursday, May 1st, Justin Schreiber sold 21,995 shares of LifeMD stock. The shares were sold at an average price of $7.53, for a total transaction of $165,622.35.
• On Tuesday, April 29th, Justin Schreiber sold 50,000 shares of LifeMD stock. The stock was sold at an average price of $7.78, for a total transaction of $389,000.00.

LifeMD Stock Down 3.0%

Shares of NASDAQ LFMD traded down $0.39 during midday trading on Friday, reaching $12.55. 902,588 shares of the company's stock traded hands, compared to its average volume of 1,075,520. The company has a market cap of $570.17 million, a price-to-earnings ratio of -36.90 and a beta of 2.40. The stock's 50 day simple moving average is $11.21 and its 200-day simple moving average is $7.48. LifeMD, Inc. has a one year low of $3.99 and a one year high of $15.84.

LifeMD (NASDAQ:LFMD - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported $0.01 earnings per share for the quarter, topping analysts' consensus estimates of ($0.04) by $0.05. The company had revenue of $65.70 million for the quarter, compared to analysts' expectations of $62.47 million. Equities analysts predict that LifeMD, Inc. will post -0.56 EPS for the current fiscal year.

Hedge Funds Weigh In On LifeMD

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. GAMMA Investing LLC purchased a new stake in shares of LifeMD during the first quarter valued at about $35,000. CWM LLC lifted its position in LifeMD by 17.5% during the first quarter. CWM LLC now owns 9,050 shares of the company's stock valued at $49,000 after acquiring an additional 1,351 shares during the last quarter. ProShare Advisors LLC purchased a new stake in LifeMD during the fourth quarter valued at approximately $51,000. Balyasny Asset Management L.P. acquired a new stake in LifeMD in the fourth quarter valued at approximately $52,000. Finally, Oxford Asset Management LLP purchased a new position in LifeMD in the fourth quarter worth $52,000. Hedge funds and other institutional investors own 35.52% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on LFMD shares. Cantor Fitzgerald restated an "overweight" rating and issued a $15.00 target price on shares of LifeMD in a research note on Tuesday, March 11th. HC Wainwright reissued a "buy" rating and issued a $14.00 price objective on shares of LifeMD in a research note on Wednesday, April 30th. B. Riley upgraded LifeMD to a "strong-buy" rating in a report on Tuesday, March 11th. Finally, BTIG Research upped their target price on LifeMD from $15.00 to $18.00 and gave the stock a "buy" rating in a report on Wednesday, June 18th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $12.00.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.